Author: BioactiveCompoundLibrary

Furthermore, poly I:C pre-exposure led to increased mortality rates following secondary bacterial challenge, which appeared to be the result of a steadily rising lung and blood bacterial burden. The mechanism responsible for poly I:C-mediated impairment was dependent upon type I IFNs, as animals deficient in the common type I interferon receptor, Ifnar2/2 mice, did not display the same magnitude of impaired bacterial clearance as WT following poly I:C pre-exposure. Whether type I IFN alone is GDC-0879 sufficient to cause suppression against bacterial infection, or whether type I IFN is deleterious in the context of the immune dysregulation created by activation of “antiviral” immune responses remains to be determined. Patients treated with chronic IFN therapy often develop neutropenia and bone marrow suppression, which is the most frequent reason for dose reduction or cessation of the drug. Approximately 18–22% of subjects on interferon therapy will develop infectious complications. Interestingly, in these studies, infections were not necessarily associated with neutropenia, raising the possibility that chronic interferon therapy may have other detrimental effects on the immune system. In our model, we observe a relatively modest impairment of neutrophil recruitment in poly I:C treated WT versus Ifnar2/2 animals; however, at this timepoint, the wildtype animals already have markedly increased bacterial numbers. Therefore, in the poly I:C model, type I IFNs may have additional effects on immune cell function beyond their effects on inflammatory cell recruitment. In contrast, administration of comparably high or higher doses of the TLR7 agonists, imiquimod or gardiquimod, was not sufficient to suppress antibacterial host defense. We observed that the dose of gardiquimod used for intranasal challenge was not sufficient to induce significant levels of type I IFNs in the lung, supporting the notion that induction of type I IFNs is necessary for post-viral inhibition of bacterial clearance. This may be in part due to the fact that TLR7 expression is largely limited to plasmacytoid dendritic cells, whereas TLR3 expression is constitutive in the lung and more widespread, including pulmonary epithelial cells and macrophages. However, if higher doses of TLR7 were used or TLR7 expression were upregulated, perhaps significant amounts of type I IFN would be elaborated which may contribute to impaired bacterial clearance. Furthermore, systemic administration of TLR7 ligands have been demonstrated to reduce the number of circulating leukocytes, suggesting that activation of the TLR7 pathway may have other detrimental effects on antibacterial immunity. Although in our system we failed to demonstrate a role for TLR7 activation in inducing susceptibility to bacterial pneumonia, further studies are needed to determine whether TLR7 signaling during actual influenza and other viral infections contributes towards impaired pulmonary antibacterial defense. Viral infections have multiple effects on the host, including activation of multiple immune pathways and induction of tissue injury, which may contribute to the dysregulated immune response during secondary infections. Although poly I:C may not completely recapitulate the effects of viral infection on pulmonary host defense, we believe that our study illustrates the utility of using poly I:C as a model for viral-induced immunosuppression. Since poly I:C mimics the immune responses of viruses that either have dsRNA genomes or which undergo a dsRNA stage during replication, this model may potentially aid in the identification of molecules that would be possible candidates for “universal” mediators of postviral immunosuppression.

A 25 kDa protein, it carries a carboxy-terminal cysteine-rich motif that is homologous with a protein domain shared by members of secreted CHIR-99021 proteins such as DAN and Cerberus. Drm was identified as a novel gene that is suppressed in cells transformed by v-ras, v-src, v-raf, and v-fos. It was shown that DRM can inhibit the growth of normal but not transformed cells in culture. A possible tumor-suppressor role was proposed for drm on the basis of its down-regulation in these transformed cell lines and it was hypothesized that high levels of drm inhibit the growth or viability of normal cells, but that transformed cells are resistant to this inhibitory effect. Studies of normal development of the limb have implicated a role for Gremlin in proper establishment of limb bud morphology. Gremlin indirectly enhances FGF-mediated limb outgrowth while simultaneously inhibiting chondrogenesis and cell death. Sonic Hedgehog has also been shown to upregulate and maintain Gremlin expression, enabling Gremlin to relieve the repressive effects of BMP-4 on FGF-4 expression, yielding a net positive feedback to increase SHH. The importance of the interaction between Gremlin and the BMP signaling pathway in the normal development of the proximal-distal patterning of the lung has previously been investigated. Gremlin acts as a functional physiological antagonist that restricts BMP-4 activity to the distal bud, thereby regulating the number of branching epithelial sacs. Similarly, antagonism of BMP-4 signal using the BMP antagonist Xnoggin results in a severe reduction in distal epithelial cell types and an increase in proximal cell types. Overexpression of Gremlin in the distal lung epithelium using an SP-C promoter in mice results in transgenic lungs that phenotypically resemble proximal airways epithelium with decreased squamous epithelium. Deletion of GREM1 in mouse embryonic stem cells results in a neonatal lethal phenotype characterized by a reduction in differentiated alveoli and multi-layered epithelium in comparison to wild-type embryos. RNA and protein analysis indicates that Gremlin is frequently undetectable in multiple malignant cell lines, including neuroblastoma, glioblastoma, medulloblastoma, and colon adenocarcinoma. The pattern of expression suggests a possible role as an inhibitor of tumor progression in these lineages. Overexpression of Gremlin was sufficient to inhibit the neoplastic phenotype of both Daoy and Soas-2 cell line. Analysis of publicly-available microarray data also suggests a significant downregulation of Gremlin in tumors of the CNS. While these studies have suggested a possible tumor-suppressive role for Gremlin, recent work has shown an oncogenic role for Gremlin in other tumor types. Gremlin is over-expressed in stromal cells associated with basal cell carcinomas of the skin, and can promote cell proliferation in this model. Gremlin is also upregulated in the lung cancer cell line A549 per a semiquantitative northern blot analysis. It was recently reported that Gremlin is overexpressed in many malignant mesothelioma tissue specimens. Inhibition of Gremlin via shRNA significantly inhibited proliferation of MM cell lines. The function of Gremlin in cancer cells is controversial and appears to work in a tissue-specific manner. In lung cancer, nothing to date is known about the role of Gremlin. Thus, we performed genetic and histological analysis of Gremlin in a large number of lung AD and squamous cell carcinoma samples. mRNA and protein expression analysis of Gremlin were done in 161 matched tumor-normal pairs. Of these, 96 pairs were of AD, while 65 of the pairs were from SCC.

This current study and the recent work of Wang et al suggests an oncogenic role for Gremlin in thoracic malignancies. This difference in tumor-suppressive or tumor-proliferative role for Gremlin appears to be a cell-type dependent effect. Topol et al and Chen et al have shown previously that overexpression of Gremlin can inhibit proliferation in tumor-derived cell lines Daoy and Saos-2. This finding is in concordance with published microarray data showing that Gremlin is consistently downregulated in tumors of the CNS in comparison to matched normals. Thus, overexpression of Gremlin in certain organs such as lung may promote tumor growth, while down-regulation of Gremlin in other organs such as brain may inhibit tumor growth. The mechanism by which Gremlin enhances proliferation in lung AD PB 203580 remains unclear. Recent developments in the role of BMP2/4 in tumorigenesis and Gremlin’s role in angiogenesis may provide novel directions to elucidate the mechanism by which Gremlin can induce proliferation in lung AD. The ability of Gremlin to antagonize members of the BMP family has previously been well-documented. However, the role of the BMP2/4 proteins in tumorigenesis is controversial. As recently reviewed by Singh and Morris, the BMP2/4 proteins are commonly shown to have anti-tumorigenic roles, such as the negative regulation of A549 cell line growth by BMP4 in Buckley, et al. However, BMP2 has been shown in some settings to enhance tumor growth in vivo due to activation of Smad-1/5. Gremlin can bind the VEGF receptor-2 in a BMPindependent manner. This binding activates VEGFR2 in endothelial cells, culminating in a VEGFR2-dependent angiogenic response in vitro and in vivo. In addition, Costello et al identified Gremlin as a highly significant member of a 90 gene cohort selectively upregulated in hypoxic primary human pulmonary microvascular cells. We tested whether increased normal lung cell growth induced by GREM1 transfection was BMP2-dependent. MRC-5 fibroblast cells with GREM1 transfection were incubated with BMP2. Addition of high-concentration BMP-2 had no effect on the growth of GREM1-transfected cells. This suggests that GREM1 increases cell growth through a BMPindependent pathway and further study will be required to better elucidate the mechanism for the tissue-specific function of Gremlin. In summary, we present evidence that Gremlin is significantly overexpressed in human adenocarcinoma of the lung. Overexpression of Gremlin increases proliferation of both lung epithelial and fibroblast cell lines. Taken together, these studies suggest an oncogenic role for Gremlin in lung adenocarcinoma. RA, a systemic autoimmune disease, is characterized by chronic joint inflammation, cartilage destruction and bone erosions. Numerous experimental data indicate that IL-17A plays an important role in the pathogenesis of RA. IL-17-deficient mice demonstrate a markedly attenuated form of collagen-induced arthritis, neutralization of IL17 during induction of experimental arthritis suppresses the onset of disease, and anti-IL-17 therapy in established CIA is associated with a significant reduction of severity. IL-17 is implicated in the development of bone erosions by altering the RANKL/OPG balance, and its action may be independent of TNF-a. In human studies, IL-17 is spontaneously produced by RA synovial membrane cultures, high levels have been observed in the synovial fluid of patients with RA, IL-17 producing CD4+ T cells have been detected in RA synovial membranes and neutralization of IL-17 seems to be effective in RA clinical trials.

A large randomized phase III assessment of the role of irinotecan added to fluorouracil/leucovorin as adjuvant treatment for colon cancer. The results presented herein explore the relationship between CNA, mRNA and outcome, and contribute to a comprehensive molecular overview of stage-II/III colon cancer, which is paramount for refining patient classification and effective treatment. The most prominent novel amplicons identified in this study include 12 p13.33 and multiple loci on 20 q. The 12 p13.33 amplicon encodes the intriguing candidate WNK1, a member of the WNK family of serine/threonine kinases which affect MAPK signaling and a variety of cancer hallmarks including cell cycle progression, evasion of apoptosis, invasion and metastasis. The complex pattern of gains and amplification on chromosome 20 q suggest multiple oncogenic drivers on this chromosome arm, consistent with observations in breast tumors and other cancer types. The 20 q13.12 amplicon, which was observed in multiple tumors and is the most significant GISTIC peak on 20 q, encodes 11 genes, none of which have been unequivocally described as oncogenic drivers in colon cancer. Nonetheless, the reported functions of some of these genes suggest that further investigation is warranted. For example, the transcription factor HNF4A controls epithelial cell polarity and promotes gut neoplasia in mice. WISP2 regulates the activity of the transforming growth factor aˆ signaling pathway and expression of genes associated with the epithelial-to-mesenchymal transition. The peak at 20 q13.31 encodes BMP7, a member of the TGFaˆ superfamily of proteins whose overexpression in colorectal cancer significantly correlates with markers of pathological aggressiveness such as liver BKM120 metastasis and is an independent prognostic factor of overall survival. Functional characterization of these and other candidate oncogenes in colon cancer cell culture, patient-derived xenografts, or genetically engineered mouse models will help elucidate potential functional implications. Pathway analysis presented previously provides not only a better understanding of the possible biological context of candidate CNA drivers but also help to infer other genes on the altered pathway for which therapeutic options may be available. On the other hand, survival analysis shows improved overall survival for the sample segment with chr20 q13.33 amplification. This association contrasts with findings of another group who reported amplification of 20 q13 is indicating worse overall survival in sporadic colorectal cancers. The exact basis for this discrepancy with our findings for is not clear, although the analyses of Aust et al. were on a substantially smaller cohort. Our analyses of associations between CNA and outcome in this set of stage II/III colon cancers revealed three loci that were significantly associated with overall survival or recurrence free survival. Deletion of the distal tip of chromosome 10 p was associated with poor OS and RFS, while an interstitial deletion of chromosome 19 p was associated with poor OS, and gain of 20 q was associated with significantly better OS in stage III tumors. While 10 p deletions, 19 p deletions, and 20 q gains have been previously reported in stage II/III colon cancers, none of these loci have been previously linked to outcome in these tumors. Conversely, we did not observe significant associations of outcome to previously reported CNAs such as deletion of 16 p13.2 in stage II/III colon cancer, or deletion of 5 q34 and gain of 13 q22.1 in stage II tumors. One potential explanation for these apparent discrepancies may relate to the limited power of the respective studies.

Increased in placentas of TLR3/7/8 agonist-treated mice, potentiate a T helper cell type 17 immune response characteristic of PE. More studies are needed to determine the temporal and GSI-IX functional effects of altered placental gene expression including the placental downregulation of osteopontin and IL-18 and their role in the development of PE. Similar to TLR3 activation, TLR7/8 activation during pregnancy in mice caused pregnancy-dependent hypertension, endothelial dysfunction, splenomegaly, and an increased incidence of fetal demise. Importantly, blood pressure and endothelial function were not affected by TLR7 or TLR7/8 activation in non-pregnant mice. These findings demonstrate that placental activation of TLR3/7/8 is crucial for the development of endothelial dysfunction and hypertension during pregnancy. Fetal demise in mice likely results from placental dysfunction and decreased placental perfusion and somewhat mimics intra-uterine growth restriction, commonly seen in women with PE. We reported that TLR3 ligation in mice increased the incidence of fetal demise, and almost identical results were seen in TLR7 as well as TLR7/8 agonist-treated mice. A previous study found that rats treated with the TLR4 agonist lipopolysaccharide at gestational day 14.5 also exhibited increased fetal demise as a result of decreased placental perfusion. Although TLR3 and TLR7 activation induced proteinuria, TLR7/ 8 activation did not. Some studies have demonstrated that not only is TLR8 functional in mice, but that it may suppress TLR7-mediated effects. Demaria and colleagues reported that Tlr82/2 mice develop autoimmune glomerulonephritis due to excessive TLR7 expression and activation, and that this was attenuated in double Tlr72/ 2/ Tlr82/2 mice. Unfortunately, urinary protein concentrations were not measured, but their findings together with our results suggest that the stimulation of renal, not placental, TLR8 may have a protective effect on renal function. Nonetheless, excessive activation of placental TLR7/8 is sufficient to induce pregnancydependent hypertension and endothelial dysfunction similar to that induced by TLR3 activation. However, examination of the role of TLR8 signaling in the mouse and how this might contribute to the development of PE-like symptoms is needed. If TLR8 signaling in mice is found to be non-functional, then it is likely that the mechanisms that cause PE in CLO97-treated mice are due to TLR7 activation, similar to that of R837-treated mice. Placental activation of TLR3/7/8 by dsRNA and ssRNA could arise from latent viruses, viruses acquired during gestation, as well as excessive cellular necrosis/apoptosis resulting from aberrant implantation, placentation, placental hypoxia, and/or trophoblast invasion. While extracellular heterologous RNA levels are normally low, high levels of extracellular heterologous RNA are evident at sites of inflammation and tissue necrosis, similar to that of dsRNA and ssRNA. Whether heterologous RNA can also activate TLR7/8 is unknown currently. While TLR3 signals through Toll-IL-1 receptordomain-containing adaptor inducing interferon-b, TLR7 and TLR8 signal through myeloid differentiation marker 88. However, both pathways converge to activate NF-kB leading to the transcription of numerous pro-inflammatory chemokines and cytokines. Inflammation is necessary for placental and fetal development, however excessive inflammation resulting from persistent placental TLR3/7/8 activation may explain the increase in circulating pro-inflammatory cytokines evident in women with PE. Here we demonstrate that TLR3, TLR7, and TLR8 levels are significantly increased in placentas from PE women at delivery.